Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + cytarabine + mercaptopurine
- Development stage
- Unknown
- Lead developer
- Sun Yat-sen University
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
cyclophosphamide + cytarabine + mercaptopurine is a combination chemotherapy regimen utilized as the second part of the reinduction phase (Phase 2) in a modified BFM-95 protocol. This specific regimen is being evaluated by Sun Yat-sen University for the treatment of adult patients with newly diagnosed T-lymphoblastic lymphoma (T-LBL). The combination consists of cyclophosphamide, an alkylating agent that cross-links DNA; cytarabine, a pyrimidine analog that inhibits DNA polymerase; and mercaptopurine, a purine antimetabolite. Together, these agents provide intensive consolidation therapy intended to eliminate residual malignant lymphoblasts following initial induction and reinduction phase 1 treatments. This protocol is part of a prospective Phase II study (NCT02562924) aimed at improving outcomes in adult T-LBL patients.
- Other names
- reinduction phase2-Sun Yat-sen University-T-lymphoblastic lymphomaModified BFM-95 reinduction phase 2
02
Targets
PPAT (Amidophosphoribosyltransferase)DNADNA polymerase family
Beyond the preview
Go deeper on cyclophosphamide + cytarabine + mercaptopurine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + cytarabine + mercaptopurine.